Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

BGLC vs OIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGLC Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–2 Matrix Metrics)

BGLC Overall Winner 6-Pillar Tally: BGLC 3 – 0 OIO (3 Tie) Matrix Metrics: BGLC 6 – 2 OIO

As of Nov 17, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over OIO (OIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGLC carries a Unified Composite Score of 47.9/100 (HOLD) at $0.71 (N/M Forward P/E, -88.2% operating margin), whereas OIO carries 36.4/100 (SELL) at $1.68 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: BGLC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5); meanwhile OIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGLC vs OIO
BGLC NASDAQ Head-to-Head Winner
BioNexus Gene Lab Corp Common stock
Services-Medical Laboratories
$0.71
-13.43% 1D
Market Cap $2.4M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 1.33β · 84% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 53.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 34
RSI-14: 33.5 · SMA20: $0.99 · SMA50: $1.21
OIO US Equity
OIO
Institutional Equity
$1.68
-1.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.14β · 53% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 22.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 44
RSI-14: 44.3 · SMA20: $1.81 · SMA50: $1.79

6-Pillar Scorecard Institutional Category Breakdown (BGLC 3 – 0 OIO)

Columns: Metric · BGLC · OIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BGLC
Revenue Growth (YoY) -96.6% N/A
Earnings Growth (YoY) -95.0% N/A
TTM Revenue (USD) $3.1M N/A
Market Cap $2.4M N/A
3. Profitability & Quality BGLC
Gross Margin 12.3% N/A
Operating Margin -88.2% N/A
Net Profit Margin -82.4% N/A
Return on Equity (ROE) -33.7% N/A
4. Balance Sheet & Cash Flow BGLC
Cash Generation (TTM) -$1.2M N/A
Cash Flow Margin -38.1% N/A
Net Cash / Leverage $3.7M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGLC (6) vs OIO (2)
Institutional Metric BGLC OIO Criterion Row Edge
Market Capitalization
Scale
$2.4M N/A Larger Scale BGLC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-96.6% N/A Higher Growth BGLC
Operating Margin (TTM)
Profitability
-88.2% N/A Higher Margin BGLC
Net Profit Margin
Profitability
-82.4% N/A Higher Margin BGLC
Return on Equity (ROE)
Capital Efficiency
-33.7% N/A Higher ROE BGLC
52-Week Range Position
Momentum
1% ($1–$5) 5% ($1–$8) Stronger Trend OIO
Beta / 30D Volatility
Risk Regime
1.33β · 84% Vol -0.14β · 53% Vol Lower Realized Risk OIO
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite BGLC
Trailing 12M Revenue (USD)
Operating Scale
$3.1M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
12.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.2M ($3.7M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OIO +35.33 pp
BGLC: -42.19% · OIO: -6.86%
3M Horizon OIO +43.39 pp
BGLC: -55.38% · OIO: -11.99%
6M Horizon OIO +53.55 pp
BGLC: -64.84% · OIO: -11.29%
1Y Horizon OIO +10.99 pp
BGLC: -67.44% · OIO: -56.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGLC vs OIO. Trailing 12-month operating profitability (BGLC -88.2% vs OIO N/A) and valuation multiples (BGLC N/M vs OIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BGLC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.1M
Gross Margin12.3%
Op. Margin-88.2%
ROE / Fwd P/E-33.7% · N/M
OIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGLC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGLC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGLC Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $2.4M market capitalization and -88.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OIO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGLC vs OIO Key Questions & Quantitative Answers

As of Nov 17, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over OIO (OIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGLC carries a Unified Composite Score of 47.9/100 (HOLD) at $0.71 (N/M Forward P/E, -88.2% operating margin), whereas OIO carries 36.4/100 (SELL) at $1.68 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: BGLC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5); meanwhile OIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGLC leads the Growth & Scale pillar: BGLC posts -96.6% YoY revenue growth and -95.0% YoY earnings growth on $3.1M TTM revenue (12.3% gross margin, -88.2% operating margin), compared with OIO at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BGLC generates $3.1M in USD-normalized revenue versus N/A for OIO. In operating R&D and SG&A reinvestment, BGLC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OIO.

BGLC and OIO trade at balanced relative valuation multiples. BGLC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-38.1% FCF margin), whereas OIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGLC (-33.7% ROE) versus OIO (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BGLC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.33β · 84% Vol realized risk). By comparison, OIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.14β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.